510(k) device
Bead Block (100 - 300µm
Biocompatibles UK Ltd (Part of Boston Scientific Corporation · Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia (NOY, Class II) · First FDA decision Apr 20, 2021, newest Apr 20, 2021Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "Bead Block 100"
MAUDE reports
0
Brand "Bead Block 100", since 2015
PubMed studies
0
Mentioning "Bead Block 100"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Bead Block (100 - 300µm
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)Local determinationIn effectL38378CGS Administrators, LLCUpdated Mar 25, 2026
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Bead Block 100", any status and sponsor, newest update first.
- Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular CarcinomaPivotal-lookingCompleted
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT00539643 · 101 participants · Start Nov 2007 · Primary completion Jun 17, 2022
Device: Bead Block microspheres · For: Hepatocellular Carcinoma; Liver Cancer; Hepatoma
Sites: New York, New York
- Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular CarcinomaPivotal-lookingStatus unknown
IRCCS Azienda Ospedaliero-Universitaria di BolognaAcademic, hospital or other
NCT04803019 · 154 participants (planned) · Start Dec 4, 2019 · Primary completion Apr 30, 2022
Device: TAE · For: Carcinoma, Hepatocellular
Sites: Bologna, Italy
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Bead Block 100", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NOY
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Bead Block 100"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NOY.
- HydroPearl MicrospheresMicroVention, Inc. · 510(k) 2020
- Embozene Color-Advanced MicrospheresBoston Scientific · 510(k) 2018
- Embosphere MicrospheresBiosphere Medical, S.A. · De Novo 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.